Brief: Transgene, Bioinvent Get ANSM Approval For Phase I/IIa Trial
19/01/2021 06:39
Jan 19 (Reuters) - BioInvent International AB BINV.ST :
* TRANSGENE AND BIOINVENT RECEIVE APPROVAL FROM ANSM TO
PROCEED
WITH PHASE I/IIA TRIAL OF ANTI-CTLA4-ARMED ONCOLYTIC VIRUS
BT-001 IN SOLID TUMORS
* FIRST PATIENT IS EXPECTED TO BE ENROLLED IN THIS TRIAL IN
UPCOMING WEEKS
Source text for Eikon: ID:nBwbFCNXra
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))